Dae Won Park

Dae Won Park

Auto-generated profile, based on publicly available information

Dae Won Park

Research Institute, GENENCELL Co., Ltd., Yongin 16950, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
SJSeon-A Jang
Seon-A Jang
DPDae Won Park
Dae Won Park
ESEun Hwa Sohn
Eun Hwa Sohn
SLSung Ryul Lee
Sung Ryul Lee
SKSe Chan Kang
Se Chan Kang

1 January 2020 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
DPDae Won Park
Dae Won Park
HJHyelin Jeon
Hyelin Jeon
RSRina So
Rina So
SKSe Chan Kang
Se Chan Kang
Park DW, et al. Nutr Res Pract. 2020 Jun;14(3):203-217. https://doi.org/10.4162/nrp.2020.14.3.203

12 August 2021 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
JHJeon Hwang-Bo
Jeon Hwang-Bo
BKByungwook Kim
Byungwook Kim
DPDae Won Park
Dae Won Park
Yeong-Geun LeeYeong-Geun Lee
Yeong-Geun Lee
JKJung Eun Kwon
Jung Eun Kwon
SKSe Chan Kang
Se Chan Kang
Purpose: Herpes zoster (HZ), or shingles, is a clinical syndrome resulting from the reactivation of latent varicella zoster virus (VZV) within the sensory ganglia. We evaluated the safety and tolerability of ES16001 (ethanol extract of Elaeocarpus sylvestris var. ellipticus), a novel inhibitor of varicella zoster virus reactivation in healthy adults. Method: Single-center, randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD, respectively) studies were conducted in 20- to 45-year-old healthy adults without chronic disease. In the SAD study (n = 32), subjects randomly received a single oral dose of 240, 480, 960, or 1440 mg ES16001 or a placebo. In the MAD study (n = 16), subjects randomly received once daily doses of 480 or 960 mg ES16001 or a placebo for 5 days. The safety and tolerability of the drug were evaluated by monitoring participants’ treatment emergent adverse events (TEAEs) and vital signs, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests. Results: In the SAD study, 11 adverse reactions were seen in 5 subjects, and in the MAD study, 8 adverse reactions were seen in 6 subjects. All adverse reactions were mild, and no serious adverse reactions occurred. The most common adverse reaction was an increase in alanine aminotransferase (ALT), but all test values were in the clinically non-significant range, and their clinical significance was judged to be small considering the fact that most of the test values returned to normal immediately after the end of drug administration. Conclusion: ES16001 has good safety and tolerability when administered both once and repeatedly to healthy subjects. Further research is needed to identify any possible drug-induced hepatotoxicity, which appears infrequently. Our findings provide a rationale for further clinical investigations of ES16001 for the prevention of HZ. Trial registration: CRIS, KCT0006066. Registered 7 April 2021—Retrospectively registered, https://cris.nih.go.kr/cris/search/detailSearch.do/19071).

1 January 2021 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
YLYoon Seo Lee
Yoon Seo Lee
HJHyelin Jeon
Hyelin Jeon
YHYang-Mi Her
Yang-Mi Her
DLDa Eun Lee
Da Eun Lee
YJYong Joon Jeong
Yong Joon Jeong
SKSe Chan Kang
Se Chan Kang
Lee YS, et al. Nutr Res Pract. 2021 Dec;15(6):715-731. https://doi.org/10.4162/nrp.2021.15.6.715

1 January 2025 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
HLHyun Sook Lee
Hyun Sook Lee
JJJae In Jung
Jae In Jung
SLSeungtae Lim
Seungtae Lim
DPDae Won Park
Dae Won Park
SLSeong Ho Lee
Seong Ho Lee
EKEun Ji Kim
Eun Ji Kim
Lee HS, et al. Nutr Res Pract. 2025 Oct;19(5):682-697. https://doi.org/10.4162/nrp.2025.19.5.682